Strattera 40 mg used

Working to find correct dose, but amazing results. At first, strattera was no effective, im all emotional fifth day i cried because my girlfriends didnt have sex with me and im felt useless. But strattera hits Its like everything was more clear, my focus way better and life is really good. It was like I could finally do things. Although the lamictal is geared towards mood regulation I found it to be x more effective when taken with the straterra. I had a few side effects in the beginning such as anxiety but that fell off the second day I took it.

I would definitely recommend taking this. In contrast, when obtaining Strattera, a mere call or fax to a pharmacy is all it takes to get the medication refilled.

Despite these benefits of Strattera, consistent with all medications whether it is a stimulant or non-stimulant, there are precautions that should be taken when taking Strattera.

If any of the following conditions refers to you or your child, it is important to inform your treating physician prior to being prescribed Strattera treatment. Strattera can be prescribed in 10 mg, 18 mg, 25 mg, or 40 mg hard capsules. Each hard capsule contains atomoxetine hydrochloride, which is equivalent to 10 mg, 18 mg, 25 mg, or 40 mg of atomoxetine.

The recommended maintenance daily dose is 40 to 80 mg, but not higher than 1. The total daily dose of Strattera should not exceed mg. Strattera is considered an instant-release medication, which begins to work shortly thereafter a patient takes a dose.

Strattera is typically prescribed for a patient to be taken either once or twice daily. When prescribed as a single time dose, taking Strattera early in the morning is the best time.

In contrast, when taken twice daily, one Strattera pill should be taken in the morning and the second one in the late afternoon or early evening. Irrespective of dosing schedule, Strattera should not be taken after 6 p. Strattera may be taken with or without food at the discretion of the patient. Geriatric Use The safety, efficacy and pharmacokinetics of Strattera in geriatric patients have not been evaluated. Strattera can therefore be administered to ADHD patients with end stage renal disease or lesser degrees of renal insufficiency using the normal dosing regimen.

Gender Gender did not influence atomoxetine disposition. Ethnic Origin Ethnic origin did not influence atomoxetine disposition except that PMs are more common in Caucasians. Out of patients who entered the acute treatment phase, The primary reason for discontinuation in both the atomoxetine 38 of 76 patients, There have been postmarketing reports of tics [see Adverse Reactions 6. Anxiety in patients with ADHD and comorbid Anxiety Disorders — In two post-marketing, double-blind, placebo-controlled trials, it has been demonstrated that treating patients with ADHD and comorbid anxiety disorders with Strattera does not worsen their anxiety.

In a week double-blind, placebo-controlled trial, patients, aged , who met DSM-IV criteria for ADHD and at least one of the anxiety disorders of separation anxiety disorder, generalized anxiety disorder or social phobia were randomized. Following a 2-week double-blind placebo lead-in, Strattera was initiated at 0.

There have been postmarketing reports of anxiety [see Adverse Reactions 6. Drug Abuse and Dependence Strattera is not a controlled substance.

Abuse In a randomized, double-blind, placebo-controlled, abuse-potential study in adults comparing effects of Strattera and placebo, Strattera was not associated with a pattern of response that suggested stimulant or euphoriant properties. There was no evidence of symptom rebound or adverse reactions suggesting a drug-discontinuation or withdrawal syndrome.

Animal Experience — Drug discrimination studies in rats and monkeys showed inconsistent stimulus generalization between atomoxetine and cocaine. Overdosage Human Experience There is limited clinical trial experience with Strattera overdose. During postmarketing, there have been fatalities reported involving a mixed ingestion overdose of Strattera and at least one other drug.

There have been no reports of death involving overdose of Strattera alone, including intentional overdoses at amounts up to mg.

In some cases of overdose involving Strattera, seizures have been reported. The most commonly reported symptoms accompanying acute and chronic overdoses of Strattera were gastrointestinal symptoms, somnolence, dizziness, tremor, and abnormal behavior.

Hyperactivity and agitation have also been reported. Investigator administered and scored. The exposure-efficacy relationship was similar to that observed between dose and efficacy with median exposures at the two highest doses resulting in near maximal changes from baseline [see Clinical Studies]. No large changes in QTc interval i. However, small changes in QTc interval cannot be excluded from the current study, because the study failed to demonstrate assay sensitivity.

There was a slight increase in QTc interval with increased atomoxetine concentration. Pharmacokinetics Atomoxetine is well-absorbed after oral administration and is minimally affected by food. It is eliminated primarily by oxidative metabolism through the cytochrome P 2D6 CYP2D6 enzymatic pathway and subsequent glucuronidation.

Atomoxetine has a half-life of about 5 hours. These individuals have reduced activity in this pathway resulting in fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination plasma half-life of about 24 hours of atomoxetine compared with people with normal activity [extensive metabolizers EMs ].

Drugs that inhibit CYP2D6, such as fluoxetine , paroxetine, and quinidine, cause similar increases in exposure. The pharmacokinetics of atomoxetine have been evaluated in more than children and adolescents in selected clinical trials, primarily using population pharmacokinetic studies. Single-dose and steady-state individual pharmacokinetic data were also obtained in children, adolescents, and adults. Clearance and volume of distribution after adjustment for body weight were also similar.

Maximal plasma concentrations Cmax are reached approximately 1 to 2 hours after dosing. The steady-state volume of distribution after intravenous administration is 0. Volume of distribution is similar across the patient weight range after normalizing for body weight.

People with reduced activity in this pathway PMs have higher plasma concentrations of atomoxetine compared with people with normal activity EMs. If this occurs, rinse your eyes with water. Ask your doctor or pharmacist how to safely handle and dispose of a broken capsule. While taking Strattera, your doctor will need to check your progress at regular visits. Your heart rate, blood pressure, height and weight may also need to be checked often.

Store at room temperature away from moisture and heat. Increase dose to 1. Dosage Information in more detail What happens if I miss a dose? Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose. What happens if I overdose? Seek emergency medical attention or call the Poison Help line at Overdose symptoms may include drowsiness, dizziness, stomach problems, tremors, or unusual behavior.

What should I avoid while taking Strattera?

Tags: nexium card canada medical abortion mifeprex misoprostol t�c dỴng thuốc misoprostol stada